Meeting
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
Authors
Michelle Hsu
Mayo Clinic Rochester, Rochester, MN
Michelle Hsu , Zesheng An , Joanina Gicobi , Tianxiao Xu , Susan Harrington , Henan Zhang , Kevin Pavelko , Jacob Hirdler , Christine M. Lohse , Reza Nabavizadeh , Rodrigo Pessoa , Vidit Sharma , Houston R. Thompson , Bradley C. Leibovich , Haidong Dong , Fabrice Lucien
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 458)
DOI
10.1200/JCO.2024.42.4_suppl.458
Abstract #
458
Poster Bd #
J19
Abstract Disclosures
Similar Posters
First Author: Igor Tsaur
Poster
2017 Genitourinary Cancers Symposium
Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Jean-Christophe Pignon
Poster
2022 ASCO Annual Meeting
Comprehensive immune profiling unravels evolution of spatial distribution and immune repertoire in tumor microenvironment from primary to metastatic triple-negative breast cancer.
First Author: Weihua Guo
First Author: Cailin Joyce